Mycapssa (octreotide) - Chiesi
Comprehensive design and characterization of pH-gradient-loaded donkey-milk exosomes for oral octreotide delivery: A bench-to-in silico roadmap. (PubMed, Int J Pharm) - Mar 15, 2026 - "While an oral octreotide formulation (Mycapssa®) utilizing transient permeability enhancement has recently been FDA-approved, its clinical utility is often constrained by strict fasting requirements and reliance on the transient disruption of intestinal tight junctions...This study provides the first proof-of-concept that donkey-milk exosomes can enable effective oral delivery of octreotide. By combining stable encapsulation, epithelial transport facilitation, predictive modeling, and in-vivo validation, this platform offers a scalable and broadly applicable strategy for transforming injectable peptides and biologics into oral therapeutics." 
Journal • ANXA2 • CD63 • CD81 • CD9 • MFGE8
http://www.ncbi.nlm.nih.gov/pubmed/41831704
 
Aakash Nathani; Arvind Bagde; Darren Anderson; Li Sun; Mandip Singh; Mounika Aare; Sandeep Chary Padakanti; Satyanarayan Dev; Yan Li
 
Mar 15, 2026
 
Prev Next